Thu, Jul 24, 2014, 10:04 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Ironwood Pharmaceuticals, Inc. Message Board

galaberge 102 posts  |  Last Activity: 1 minute 41 seconds ago Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Careful

    by jjworldwide 35 minutes ago
    galaberge galaberge 1 minute 41 seconds ago Flag

    Congrats. You are so right. We are not in a hurry to make any mistake. The mngt should take the time it needs to do a perfect job when ready to disclose all the results we are waiting for.

    Long and strong HZNP

    Sentiment: Strong Buy

  • galaberge galaberge Jul 23, 2014 5:53 AM Flag

    Unfortunately not. But who cares for 5 days range ? It will be a real positive surprise. Every product has seen sales going up significantly. Have a good day.

    Long and strong HZNP

    Sentiment: Strong Buy

  • galaberge galaberge Jul 23, 2014 5:49 AM Flag

    It should be a buyout at $22-25. We have only 58.45 Million shares so $1.5 Billion is the very minimum price for Trimesta presently.

    Long and strong SYN

    Sentiment: Strong Buy

  • Jennifer Maynard, Ph.D., of The University of Texas at Austin's McKetta Department of Chemical Engineering will highlight Synthetic Biologics' SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis (whooping cough) in a poster presentation. Dr. Maynard is scheduled to present at the Microbial Toxins & Pathogenicity conference held by Gordon Research Conferences on July 20-25, 2014, in Waterville Valley, NH.

    I quote :

    "Synthetic Biologics is developing SYN-005 through its Exclusive Channel Collaboration with Intrexon Corporation (XON) and academic researchers at The University of Texas at Austin to target and neutralize the pertussis toxin in order to reduce morbidity and mortality in infected infants. Pertussis is a highly contagious disease caused by the bacteria Bordetella pertussis (B. pertussis) with symptoms that may include chronic coughing and subsequent breathing difficulties. According to the World Health Organization, there are approximately 50 million worldwide cases of whooping cough each year, leading to an estimated 300,000 deaths, primarily among young, unvaccinated infants."

    It's the beginning of news in the 2nd H-2014 !

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Jul 18, 2014 3:42 PM Flag

    I would like to see you posting in French and calculate how many mistakes you would do. I know it's "glued TO his chair" and anyway you have well understood what I was thinking of you Bruuuuuuuuce....! BTW I am not a Frenchman from France but from the marvelous French Quebec province of Canada.

    Sentiment: Strong Buy

  • galaberge galaberge Jul 16, 2014 7:27 PM Flag

    I am with HZNP since Jan 2011!

    Sentiment: Strong Buy

  • Reply to

    Too quiet to have nothing cooking!

    by rhmass2007 Jul 16, 2014 6:10 PM
    galaberge galaberge Jul 16, 2014 6:23 PM Flag

    You're absolutely right. Time plays for the longs.

    Wait and watch what will happen pretty soon. Riley and Kirk are very brilliant and they don't speak for nothing. They want to have their shareholders very very happy.

    Long and strong SYN

    Sentiment: Strong Buy

  • He has no share but he's very frustrated man having lost too much in trying to short HZNP. Now he relentlessly harass this MB with his frustration. Poor i...t

    Time plays for the longs.

    Long and strong HZNP

    Sentiment: Strong Buy

  • It's a shame to entertain a message board with such exaggerated things ! I see that many have nothing better to do than being paranoiac; they should sell and buy GE, IBM, Netflix....

    Sentiment: Strong Buy

  • Reply to

    technically, not good

    by topgunbioinvestor Jul 11, 2014 12:49 PM
    galaberge galaberge Jul 11, 2014 2:16 PM Flag

    postbusters-From where this topgun (?%$&?%) coming from ?? A real #$%$ A small volatility while en route to $30.

    Sentiment: Strong Buy

  • A: "Get rid of the bozos in Wall Street who play to be gurus of the stock markets. Seriously, fire them immediately"

    A joke these few people who can't predict what kind of socks they will wear in 3 days.

    Long and strong HZNP

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 8, 2014 5:57 AM Flag

    Or this link just ggogle "http://finance.yahoo.com/news/synthetic-biologics-reports-ucla-announcement-194500444.html"

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 8, 2014 5:47 AM Flag

    Link to be consulted: Google "cxvascularDOTcom/nn-latest-news/neuro-news---latest-news/phase-ii-study-of-trimesta-for-relapsing-remitting-multiple-sclerosis-yields-positive-efficacy-and-safety-results" for the proof of the press release.

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 7, 2014 10:30 PM Flag

    Trimesta's differentiated mechanism of action, combined with the convenience of once-daily oral dosing, may potentially make it an ideal added therapy to address this underserved $14.1 billion worldwide market," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics."

    So to summarise we have the ACTUAL facts ;

    1- The results after 12 months AND 24 months were 47 % decrease in annualized MS relapse rate (due to the word P-E-R-S-I-S-T-E-D....!!! )

    2-Moreover we had In addition a significant improvement in cognitive function observed at 12 months AND at 24 months as measured by PASAT

    3-Copaxone (from TEVA) alone had ONLY 32% improvement after 24 months

    So if you are 1 of the 260,000 US women and you have to choose between a drug giving almost 50% chances to be cured and the Copaxone (not curing you) with his 32%, WHAT DO YOU CHOOSE ? That's the main question. And the answer is anyone with an ounce of intelligence and judgment will ask for Trimesta. The other 50% not cured will have the same ACTUAL benefits of the ACTUAL treatment with the Copaxone which is the SOC ! Trimesta is made with the exact dosage of the actual treatment with the Copaxone + 8 mg of Estriol.

    I am sure the Trimesta story is just beginning.....for the shareholders and for the sick women. 2/2

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 7, 2014 10:09 PM Flag

    If we re-read the press release of the Trimesta's results we see many astonishing things. Let's see what I mean.

    First I will quote and comment :

    "Dr. Voskuhl commented, "Pregnancy is known to be a period of relative protection from MS relapses, and the therapeutic effects of pregnancy hormones, including estriol, include both anti-inflammatory and neuroprotective mechanisms as evidenced in animal models of MS. We are encouraged by the topline results from this first randomized placebo-controlled trial evaluating oral estriol due to the positive impact of adjunctive therapy with estriol on the patients in this study. We look forward to continued clinical evaluation of estriol, which we believe has the potential to slow disease progression and improve quality of life for women with RRMS."
    The Phase II, double-blinded, placebo-controlled trial randomized 158 women with relapsing-remitting MS at 16 sites across the U.S. Among topline results, women receiving Trimesta plus Copaxone demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment as compared to women receiving placebo plus Copaxone. In addition, a significant improvement in cognitive function was observed at 12 months as measured by Paced Auditory Serial Addition Test (PASAT) scores. After 24 months of treatment, the reduction in relapse rate PERSISTED in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32 percent). Both treatment groups exhibited improvement in measures of cognitive function at 24 months. Treatment was safe and well tolerated with no evidence of adverse effects on breast or uterus.
    "The topline data presented today are encouraging for women with MS, including the approximately 260,000 women with MS in the United States. We believe adjunctive therapy with Trimesta has the potential to improve therapeutic outcomes for women currently taking first-line RRMS treatments. 1/2

  • Reply to

    Don't fear the haircuts

    by alien_twin Jul 7, 2014 9:32 AM
    galaberge galaberge Jul 7, 2014 9:37 AM Flag

    If you have nothing intelligent to say shut your mouth and go to another MB where you can buy shares.

    Sentiment: Strong Buy

  • This presentation is a public event and the CEO has to be factual because it's important for all the potential investors and the general audience. Also this presentation is in a written form.

    I quote :

    "3rd Annual Marcum LLP MicroCap Conference
    By Jeffrey Riley, CEO
    May 29, 2014

    Topline results presented at 2014 AAN by Dr. Voskhul demonstrated :

    1-Statiscally significant 47% decrease in annualized MS relapse rate at 12 months with Trimesta+Copaxone compared to placebo+Copaxone (p=0.03/powered for significance level 0.05)

    2-32% decrease in annualized relapse rate at 24 months with Trimesta+Copaxone compared to placebo+Copaxone (p=0.15/powered for significance level 0.10)

    • Per study protocol, investigators anticipated a 29% decrease in relapse rate at both 12 and 24 months

    3-Clinically significant near-normalization of cognitive scores at 12 months of therapy with Trimesta+Copaxone

    • Unique neuroprotective effect of oral estriol highly significant to MS community

    4-Trimesta+Copaxone was generally safe and well tolerated

    Next planned steps for Trimesta for relapsing-remitting MS :

    • Demonstrated therapeutic potential and safety of oral estriol support ongoing strategic partnering efforts
    • Lead principal investigator, Dr. Voskuhl, to report detailed study results (2H-2014)"

    So the real facts are per study protocol, investigators anticipated a 29% decrease in relapse rate at both 12 and 24 months while SYN achieved 47% and 32% respectively !!!

    Trimesta is a success based on the the initial protocol and it's the reason we can call these results as VERY POSITIVE.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Looks Runnerish!!!

    by fanelli_robert Jun 30, 2014 11:38 AM
    galaberge galaberge Jul 1, 2014 1:40 PM Flag

    BUMP BUMP

    Sentiment: Strong Buy

  • galaberge by galaberge Jul 1, 2014 12:34 PM Flag

    I hate these gaps when the markets open at 09:30. Not all the gaps should be closed (breakaway gap don't need to be closed for example) but most of them have to be closed.

    Long and strong SYN

    Sentiment: Strong Buy

  • Company Expects to Initiate C. difficile Clinical Trials in 2014

    I quote :

    "The new Clinical Advisory Board (CAB) is comprised of industry leaders Mark Wilcox, M.D., (Chairman), Curtis Donskey, M.D., Ciarán Kelly, M.D. and Tom Louie, M.D., all of whom will provide expertise and guidance on each aspect of the C. diff clinical program.

    Professor Mark Wilcox M.D., FRCPath, is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK.
    Curtis Donskey, M.D., is Associate Professor of Medicine at Case Western Reserve University School of Medicine, as well as Chairman of the Infection Control Committee at the Louis Stokes Cleveland Veterans' Affairs Medical Center.
    Ciarán P. Kelly, M.D., is Professor of medicine at Harvard Medical School, as well as Director of Gastroenterology Fellowship Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center in Boston, MA.
    Thomas Louie, M.D., is Professor of Medicine in the department of medicine and microbiology-immunology & infectious diseases at the University of Calgary in Alberta, Canada.

    "As we move closer to initiating human clinical trials of SYN-004, and build our global leadership position in the C. difficile prevention space, we are pleased to assemble this group of highly experienced and knowledgeable advisors to guide clinical development of our program," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics.

    Synthetic Biologics expects to initiate Phase Ia and Ib clinical trials to evaluate SYN-004 in the second half of 2014, with preliminary topline data expected by year-end 2014. A Phase II efficacy study of SYN-004 is expected to begin in the first half of 2015."

    Great news

    Long and strong SYN

    Sentiment: Strong Buy

IRWD
15.40+0.35(+2.33%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Baidu, Inc.
NasdaqGSThu, Jul 24, 2014 4:00 PM EDT
Visa Inc.
NYSEThu, Jul 24, 2014 4:00 PM EDT